CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer
Authors:
- Lidia KarabonLKLidia Karabon
- Edyta PawlakEdyta Pawlak
- Anna TomkiewiczATAnna Tomkiewicz
- Anna JedynakAJAnna Jedynak
- Ewa Passowicz-MuszynskaEPEwa Passowicz-Muszynska
- Katarzyna ZajdaKZKatarzyna Zajda
- Anna JonkiszAJAnna Jonkisz
- Renata JankowskaRJRenata Jankowska
- Maciej KrzakowskiMKMaciej Krzakowski
- Irena FrydeckaIFIrena Frydecka
- 1 October 2011
- journal article
- Published by Elsevier in Human Immunology
- Vol. 72 (10) , 947-954
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemiaBritish Journal of Cancer, 2004
- The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune ResponsesAnnual Review of Immunology, 2002
- Activation and inhibition of lymphocytes by costimulationJournal of Clinical Investigation, 2002
- Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T CellsThe Journal of Immunology, 2000
- Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosisClinical and Experimental Immunology, 2000
- ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28Nature, 1999
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- Manipulation of costimulatory signals to enhance antitumor T-cell responsesCurrent Opinion in Immunology, 1995
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994